You are on page 1of 2

40386 Federal Register / Vol. 70, No.

133 / Wednesday, July 13, 2005 / Notices

0871492, filed January 3, 1997, entitled ‘‘Monoclonal Antibody’’ [E–195–1990/ this notice will not be made available
‘‘Mesothelium Antigen And Methods 0–JP–19] to Morphotek, Inc., which has for public inspection and, to the extent
And Kits For Targeting It’’ [E–002–1996/ offices in Exton, Pennsylvania. The permitted by law, will not be released
1–GB–12]; United States Patent No. patent rights in these inventions have under the Freedom of Information Act,
5,320,956, issued June 14, 1996, entitled been assigned to the United States of 5 U.S.C. 552.
‘‘Monoclonal Antibody’’ [E–195–1990/ America. Dated: July 1, 2005.
0–US–20]; United States Patent No. The prospective exclusive license
territory may be worldwide, and the Steven M. Ferguson,
5,525,337, issued June 11, 1996, entitled
field of use may be limited to the use Director, Division of Technology Development
‘‘Monoclonal Antibody Binding Cell and Transfer, Office of Technology Transfer,
Surface Antigen For Diagnosing Cancer’’ of licensee’s MORAb–009 antibody for
National Institutes of Health.
[E–195–1990/0–US–21]; United States the treatment of mesothelin-expressing
cancer. [FR Doc. 05–13804 Filed 7–12–05; 8:45 am]
Patent No. 5,817,313, issued October 6,
BILLING CODE 4140–01–P
1998, entitled ‘‘Monoclonal Antibodies DATES: Only written comments and/or
And Conjugates Thereof Useful For The applications for a license which are
Treatment Of Cancer’’ [E–195–1990/0– received by the NIH Office of DEPARTMENT OF HEALTH AND
US–22]; PCT Patent Application No. Technology Transfer on or before HUMAN SERVICES
PCT/US91/07227, filed October 9, 1991, September 12, 2005 will be considered.
entitled ‘‘Monoclonal Antibody’’ [E– ADDRESSES: Requests for copies of the National Institutes of Health
195–1990/0–PCT–02]; Denmark Patent patent application, inquiries, comments,
No. 0554356, filed October 9, 1991, and other materials relating to the National Cancer Institute; Notice of
entitled ‘‘Monoclonal Antibody’’ [E– contemplated exclusive license should Closed Meeting
195–1990/0–DK–03]; United Kingdom be directed to: Jesse S. Kindra, J.D.,
Patent No. 0554356, filed October 9, M.S., Technology Licensing Specialist, Pursuant to section 10(d) of the
1991, entitled ‘‘Monoclonal Antibody’’ Office of Technology Transfer, National Federal Advisory Committee Act, as
[E–195–1990/0–GB–04]; Austrian Patent Institutes of Health, 6011 Executive amended (5 U.S.C. Appendix 2), notice
No. 0554356, filed October 9, 1991, Boulevard, Suite 325, Rockville, MD is hereby given of the following
entitled ‘‘Monoclonal Antibody’’ [E– 20852–3804; Telephone: (301) 435– meeting.
195–1990/0–AT–05]; Belgium Patent 5559; Facsimile: (301) 402–0220; E-mail: The meeting will be closed to the
No. 0554356, filed October 9, 1991, kindraj@mail.nih.gov. public in accordance with the
entitled ‘‘Monoclonal Antibody’’ [E– SUPPLEMENTARY INFORMATION: The provisions set forth in sections
195–1990/0–BE–06]; European Patent technology relates to CAK1, or 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
No. 0554356, filed October 9, 1991, ‘‘mesothelin’’, which is an antigen as amended. The grant applications and
entitled ‘‘Monoclonal Antibody’’ [E– present on the cell surface in the discussions could disclose
195–1990/0–EP–09]; French Patent No. mesothelium and on many confidential trade secrets or commercial
0554356, filed October 9, 1991, entitled mesotheliomas and ovarian cancers. property such as patentable material,
‘‘Monoclonal Antibody’’ [E–195–1990/ While the role of this differentiation and personal information concerning
0–FR–11]; German Patent No. 0554356, antigen has not yet been determined, it individuals associated with the grant
filed October 9, 1991, entitled is postulated that it may be implicated applications, the disclosure of which
‘‘Monoclonal Antibody’’ [E–195–1990/ in adhesion and in the dissemination of would constitute a clearly unwarranted
0–DE–08]; Greece Patent No. 0554356, mesotheliomas and of ovarian cancers. invasion of personal privacy.
filed October 9, 1991, entitled CAK1, therefore, is a potential target for Name of Committee: National Cancer
‘‘Monoclonal Antibody’’ [E–195–1990/ monoclonal antibodies to be used in the Institute Special Emphasis Panel, Centers of
0–GR–12]; Netherlands Patent No. diagnosis and treatment of these Cancer Nanotechnology Excellence (CCNEs).
0554356, filed October 9, 1991, entitled cancers. The gene for CAK1 has been Date: July 19–22, 2005.
‘‘Monoclonal Antibody’’ [E–195–1990/ cloned and sequenced, as embodied in Time: 6 p.m. to 5 p.m.
0–NL–15]; Italian Patent No. 0554356, the current technology. This technology, Agenda: To review and evaluate grant
filed October 9, 1991, entitled therefore, should provide a valuable applications.
‘‘Monoclonal Antibody’’ [E–195–1990/ research tool for use in the development Place: Holiday Inn Georgetown, 2101
0–IT–13]; Luxembourg Patent No. of diagnostics and/or therapeutic agents Wisconsin Ave NW., Washington, DC 20007.
0554356, filed October 9, 1991, entitled toward mesotheliomas and ovarian Contact Person: Michael B. Small, PhD,
‘‘Monoclonal Antibody’’ [E–195–1990/ cancers. Scientific Review Administrator, Research
0–LU–14]; Spanish Patent No. 0554356, The prospective exclusive license will Programs Review Branch, Division of
filed October 9, 1991, entitled be royalty bearing and will comply with Extramural Activities, National Cancer
‘‘Monoclonal Antibody’’ [E–195–1990/ the terms and conditions of 35 U.S.C. Institute, National Institutes of Health, 6116
0-ES–10]; Sweden Patent No. 0554356, 209 and 37 CFR 404.7. The prospective Executive Blvd., Room 8127, Bethesda, MD
filed October 9, 1991, entitled exclusive license may be granted unless 20892–8328, 301–402–0996,
‘‘Monoclonal Antibody’’ [E–195–1990/ smallm@mail.nih.gov.
within sixty (60) days from the date of
This notice is published less than 15 days
0–SE–16]; Switzerland Patent No. this published notice, the NIH receives prior to meeting due to scheduling conflicts.
0554356, filed October 9, 1991, entitled written evidence and argument that
‘‘Monoclonal Antibody’’ [E–195–1990/ (Catalogue of Federal Domestic Assistance
establishes that the grant of the license
Program Nos. 93.392, Cancer Construction;
0–CH–07]; Australian Patent No. would not be consistent with the 93.393, Cancer Cause and Prevention
648363, filed October 9, 1991, entitled requirements of 35 U.S.C. 209 and 37 Research; 93.394, Cancer Detection and
‘‘Monoclonal Antibody’’ [E–195–1990/ CFR 404.7. Diagnosis Research; 93.395, Cancer
0–AU–17]; Canadian Patent No. Applications for a license in the field Treatment Research; 93.396, Cancer Biology
2093928, filed October 9, 1991, entitled of use filed in response to this notice Research; 93.397, Cancer Centers Support;
‘‘Monoclonal Antibody’’ [E–195–1990/ will be treated as objections to the grant 93.398, Cancer Research Manpower; 93.399,
0–CA–18]; and Japanese Patent No. of the contemplated exclusive license. Cancer Control, National Institutes of Health,
2660241, filed October 9, 1991, entitled Comments and objections submitted to HHS)

VerDate jul<14>2003 17:40 Jul 12, 2005 Jkt 205001 PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 E:\FR\FM\13JYN1.SGM 13JYN1
Federal Register / Vol. 70, No. 133 / Wednesday, July 13, 2005 / Notices 40387

Dated: July 5, 2005. DEPARTMENT OF HEALTH AND amended (5 U.S.C. Appendix 2), notice
LaVerne Y. Stringfield, HUMAN SERVICES is hereby given of the following
Director, Office of Federal Advisory meetings.
Committee Policy. National Institutes of Health The meetings will be closed to the
[FR Doc. 05–13813 Filed 7–12–05; 8:45 am] public in accordance with the
National Cancer Institute; Notice of provisions set forth in sections 552(c)(4)
BILLING CODE 4140–01–M Closed Meeting and 552b(c)(6), Title 5 U.S.C., as
Pursuant to section 10(d) of the amended. the grant applications and the
DEPARTMENT OF HEALTH AND Federal Advisory Committee Act, as discussions could disclose confidential
HUMAN SERVICES amended (5 U.S.C. Appendix 2), notice trade secrets or commercial property
is hereby given of the following such as patentable material, and
National Institutes of Health meeting. personal information concerning
The meeting will be closed to the individuals associated with the grant
National Cancer Institute; Notice of public in accordance with the applications, the disclosure of which
Closed Meeting provisions set forth in sections would constitute a clearly unwarranted
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., invasion of personal privacy.
Pursuant to section 10(d) of the as amended. The grant applications and Name of Committee: National Center on
Federal Advisory Committee Act, as the discussions could disclose Minority Health and Health Disparities
amended (5 U.S.C. Appendix 2), notice confidential trade secrets or commercial Special Emphasis Panel, MCMHD
is hereby given of the following property such as patentable material, Community-Based Participatory Research &
meeting. and personal information concerning Outreach.
Date: July 18–20, 2005.
The meeting will be closed to the individuals associated with the grant
Time: 2 p.m. to 5 p.m.
public in accordance with the applications, the disclosure of which Agenda: To review and evaluate grant
provisions set forth in sections would constitute a clearly unwarranted applications.
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., invasion of personal privacy. Place: Embassy Suites at the Chevy Chase
as amended. The contract proposals and Name of Committee: National Cancer Pavilion, 4300 Military Road, NW.,
the discussions could disclose Institute Initial Review Group, Subcommittee Washington, DC 20015.
E—Cancer Epidemiology, Prevention & Contact Person: Merlyn M. Rodrigues, PhD,
confidential trade secrets or commercial MD, Director, Office of Extramural Activities,
property such as patentable material, Control.
Date: August 11–12, 2005. National Center On Minority Health, and
and personal information concerning Health Disparities, National Institute of
Time: 8 a.m. to 12 p.m.
individuals associated with the contract Agenda: To review and evaluate grant Health, 6707 Democracy Blvd. Suite 800,
proposals, the disclosure of which applications. Bethesda, MD 20894, (301) 402–1366,
would constitute a clearly unwarranted Place: Bethesda North Marriott, 5701 rodrigm1@mail.nih.gov.
invasion of personal privacy. Marinelli Road, North Bethesda, MD 20852. Name of Committee: National Center on
Contact Person: Mary C. Fletcher, PhD, Minority Health and Health Disparities
Name of Committee: National Cancer Special Emphasis Panel, Project EXPORT—
Scientific Review Administrator, Research
Institute Special Emphasis Panel, Lab Programs Review Branch, Division of Establishing Exploratory Centers.
Assessment of Tobacco Use Behavior & Extramural Activities, National Cancer Date: July 24–26, 2005.
Exposure Toxins. Institute, National Institutes of Health, 6116 Time: 5 p.m. to 2 p.m.
Date: August 4, 2005. Executive Boulevard, Rm 8115, Bethesda, Agenda: To review and evaluate grant
Time: 8 a.m. to 4 p.m. MD 20892, (301) 496–7413. applications.
Agenda: To review and evaluate contract (Catalogue of Federal Domestic Assistance Place: Embassy Suites at the Chevy Chase
proposals. Program Nos. 93.392, Cancer Construction; Pavilion, 4300 Military Road, NW.,
Place: Holiday Inn Select Bethesda, 8120 93.393, Cancer Cause and Prevention Washington, DC 20015.
Wisconsin Ave, Bethesda, MD 20814. Research; 93.394, Cancer Detection and Contact Person: Lorrita Watson, PhD,
Diagnosis Research; 93.395, Cancer National Center on Minority Health and
Contact Person: Joyce C. Pegues, PhD,
Treatment Research; 93.396, Cancer Biology Health Disparities, National Institutes of
Scientific Review Administrator, Special Health, 6707 Democracy Blvd., Suite 800,
Research; 93.397, Cancer Centers Support;
Review and Logistics Branch, Division of Bethesda, MD 20892–5465, 301–594–7784,
93.398, Cancer Research Manpower; 93.399,
Extramural Activities, National Cancer Cancer Control, National Institutes of Health, watsonl@ncmhd.nih.gov.
Institute, 6116 Executive Blvd. 7149, HHS) Dated: June 30, 2005.
Bethesda, MD 20892, 301/594–1286,
peguesj@mail.nih.gov. Dated: July 5, 2005. LaVerne Y. Stringfield,
LaVerne Y. Stringfield, Director, Office of Federal Advisory
(Catalogue of Federal Domestic Assistance
Director, Office of Federal Advisory Committee Policy.
Program Nos. 93.392, Cancer Construction;
Committee Policy. [FR Doc. 05–13811 Filed 7–12–05; 8:45 am]
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and [FR Doc. 05–13817 Filed 7–12–05; 8:45 am] BILLING CODE 4140–01–M

Diagnosis Research; 93.395, Cancer BILLING CODE 4140–01–M


Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support; DEPARTMENT OF HEALTH AND
93.398, Cancer Research Manpower; 93.399, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Cancer Control, National Institutes of Health, HUMAN SERVICES
HHS)
National Institutes of Health
National Institutes of Health
Dated: July 5, 2005. National Eye Institute; Notice of Closed
LaVerne Y. Stringfield, National Center on Minority Health and Meeting
Director, Office of Federal Advisory Health Disparities; Notice of Closed
Pursuant to section 10(d) of the
Committee Policy. Meetings
Federal Advisory Committee Act, as
[FR Doc. 05–13816 Filed 7–12–05; 8:45 am] Pursuant to section10(d) of the amended (5 U.S.C. Appendix 2), notice
BILLING CODE 4140–01–M Federal Advisory Committee Act, as is hereby given of a meeting of the

VerDate jul<14>2003 17:40 Jul 12, 2005 Jkt 205001 PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 E:\FR\FM\13JYN1.SGM 13JYN1